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a p value <0.10 in the univariate analysis were entered into the
Cox proportional hazard model, and the results are presented in
Fig. 1. Out of the variables, TACE therapy, older age, and PLT
>156  109/L were independently associated with poor OS in
HCC beyond the Milan criteria. In contrast, age, PLT, and vascular
invasion, but not the type of therapy, were independent indica-
tors to predict RFS. The signiﬁcant risk factors for recurrence
included therapeutic method, gamma-glutamyltransferase
(GGT), and PLT.
Thus, we suggest that patients with a high preoperative PLT
had a signiﬁcantly worse OS and RFS, as well as a higher risk of
recurrence compared to patients with a PLT 6156  109/L, which
is consistent with previous studies [3,4]. These ﬁndings support
the hypothesis that PLT could be a confounder and should be
adjusted when estimating the independent signiﬁcance of the
type of treatment or other factors. Not only was PLT a valuable,
readily available, and inexpensive parameter to predict survival
in HCC, but it was also associated with cirrhosis formation [5]
and hepatic carcinogenesis [6]. In addition, administration of
anti-platelet agents (aspirin and clopidogrel) could prevent
hepatocarcinogenesis and greatly improve OS [7].
However, no statistically signiﬁcant difference in the RFS
between PH and TACE was observed in our study (p = 0.840).
Further studies on larger cohorts are needed to validate this
ﬁnding.
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Letters to the EditorTo the Editor:
We read with interest the article by Yin et al. [1], in which they
highlighted that partial hepatectomy (PH) was superior to
transcatheter arterial chemoembolization (TACE) for patients
with resectable multiple hepatocellular carcinoma (HCC) beyond
the Milan criteria. However, their ﬁndings may need further
improvement based on the following two viewpoints.
First, the authors excluded patients whose platelet count (PLT)
was <80  109/L, which might be in view of the inﬂuence of
thrombocytopenia on therapy. In addition, enrolled patients in
the TACE group had a lower preoperative PLT compared to
patients who received PH (Yin et al., Table 1, 154.7  109/L vs.
172.3  109/L, p = 0.087 <0.10). Therefore, we speculated that
the PLT might be a potential confounder in the association
between the type of treatment and survival in HCC, while the
authors might ignore to correct it in the multivariate analysis.
Second, the authors did not compare recurrence-free survival
(RFS) between the two groups though they considered this as a
secondary outcome measure (ClinicalTrials.gov NCT00820157).
The discordance between the publication and the registration
information might decrease the validity of their ﬁndings [2].
Whether or not the high recurrence rate (68.9%) after PH affected
RFS was not reported by Yin et al.
To estimate the signiﬁcance of PLT in the prognosis of HCC, we
retrospectively analysed in our centre 213 patients (from April
2002 until August 2012) that were beyond the Milan criteria.
91 patients received PH and 122 individuals underwent TACE.
The outcomes analysed included overall survival (OS), RFS, and
recurrence. The receiver operating characteristic curve showed
an optimal cut-off value of 156  109/L for PLT with regard to
mortality. By Log-rank test, we found that the PLT was
signiﬁcantly associated with OS and recurrence. Variables with748 Journal of Hepatology 2015 vol. 62 j 739–752
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Fig. 1. Multivariate analyses of prognostic factors in hepatocellular carcinoma beyond the Milan criteria. The forest plot was drawn using STATA software: the position
of the triangle stands for the adjusted HR value, circles mark the boundaries of the 95% CI, and the vertical line (HR 1.0) corresponds to no signiﬁcance. PLT was an
independent prognostic factor for OS, RFS, and recurrence, while the type of therapy was not a valuable indictor to predict RFS. OS, overall survival, RFS, recurrence-free
survival, PLT, platelet count.
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